BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 17112722)

  • 1. Solid phase-assisted synthesis and screening of a small library of N-(4-hydroxyphenyl)retinamide (4-HPR) analogs.
    Mershon SM; Anding AL; Chapman JS; Clagett-Dame M; Stonerock LA; Curley RW
    Bioorg Med Chem Lett; 2007 Feb; 17(3):836-40. PubMed ID: 17112722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines.
    Villani MG; Appierto V; Cavadini E; Bettiga A; Prinetti A; Clagett-Dame M; Curley RW; Formelli F
    Cancer Res; 2006 Mar; 66(6):3238-47. PubMed ID: 16540676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An unhydrolyzable analogue of N-(4-hydroxyphenyl)retinamide. synthesis and preliminary biological studies.
    Weiss KL; Alshafie G; Chapman JS; Mershon SM; Abou-Issa H; Clagett-Dame M; Curley RW
    Bioorg Med Chem Lett; 2001 Jun; 11(12):1583-6. PubMed ID: 11412986
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is growth inhibition and induction of apoptosis in lung cancer cell lines by fenretinide [N-(4-hydroxyphenyl)retinamide] sufficient for cancer therapy?
    Ohlmann CH; Jung C; Jaques G
    Int J Cancer; 2002 Aug; 100(5):520-6. PubMed ID: 12124800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retinoid receptor-dependent and independent biological activities of novel fenretinide analogues and metabolites.
    Sabichi AL; Xu H; Fischer S; Zou C; Yang X; Steele VE; Kelloff GJ; Lotan R; Clifford JL
    Clin Cancer Res; 2003 Oct; 9(12):4606-13. PubMed ID: 14555536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Water-soluble derivatives of 4-oxo-N-(4-hydroxyphenyl) retinamide: synthesis and biological activity.
    Musso L; Tiberio P; Appierto V; Cincinelli R; Cavadini E; Cleris L; Daidone MG; Dallavalle S
    Chem Biol Drug Des; 2016 Oct; 88(4):608-14. PubMed ID: 27135197
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.
    Simeone AM; Deng CX; Kelloff GJ; Steele VE; Johnson MM; Tari AM
    Carcinogenesis; 2005 May; 26(5):1000-7. PubMed ID: 15695235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemopreventive activities of C-glucuronide/glycoside analogs of retinoid-O-glucuronides against breast cancer development and growth.
    Curley RW; Abou-Issa H; Panigot MJ; Repa JJ; Clagett-Dame M; Alshafie G
    Anticancer Res; 1996; 16(2):757-63. PubMed ID: 8687125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potent effect of 5-HPBR, a butanoate derivative of 4-HPR, on cell growth and apoptosis in cancer cells.
    Han HS; Kwon YJ; Park SH; Kim EJ; Rho YS; Sin HS; Um SJ
    Int J Cancer; 2004 Mar; 109(1):58-64. PubMed ID: 14735468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of N-(4-hydroxyphenyl)retinamide on apoptosis in human breast cancer cells.
    Wang TT; Phang JM
    Cancer Lett; 1996 Oct; 107(1):65-71. PubMed ID: 8913268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. p-Dodecylaminophenol derived from the synthetic retinoid, fenretinide: antitumor efficacy in vitro and in vivo against human prostate cancer and mechanism of action.
    Takahashi N; Watanabe Y; Maitani Y; Yamauchi T; Higashiyama K; Ohba T
    Int J Cancer; 2008 Feb; 122(3):689-98. PubMed ID: 17955489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitory effects of fenretinide metabolites N-[4-methoxyphenyl]retinamide (MPR) and 4-oxo-N-(4-hydroxyphenyl)retinamide (3-keto-HPR) on fenretinide molecular targets β-carotene oxygenase 1, stearoyl-CoA desaturase 1 and dihydroceramide Δ4-desaturase 1.
    Poliakov E; Samuel W; Duncan T; Gutierrez DB; Mata NL; Redmond TM
    PLoS One; 2017; 12(4):e0176487. PubMed ID: 28448568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 4-oxo-N-(4-hydroxyphenyl)retinamide: two independent ways to kill cancer cells.
    Tiberio P; Cavadini E; Abolafio G; Formelli F; Appierto V
    PLoS One; 2010 Oct; 5(10):e13362. PubMed ID: 20976277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fenretinide: induction of apoptosis and endogenous transforming growth factor beta in PC-3 prostate cancer cells.
    Roberson KM; Penland SN; Padilla GM; Selvan RS; Kim CS; Fine RL; Robertson CN
    Cell Growth Differ; 1997 Jan; 8(1):101-11. PubMed ID: 8993839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of skin carcinogenesis by phenylretinamides: retinoid receptor-independent tumor suppression.
    Xu H; Cheepala S; McCauley E; Coombes K; Xiao L; Fischer SM; Clifford JL
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):969-79. PubMed ID: 16467112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fenretinide-induced apoptosis of human head and neck squamous carcinoma cell lines.
    Scher RL; Saito W; Dodge RK; Richtsmeier WJ; Fine RL
    Otolaryngol Head Neck Surg; 1998 Apr; 118(4):464-71. PubMed ID: 9560096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo use of N-(4-hydroxyphenyl retinamide)-0-glucuronide as a breast cancer chemopreventive agent.
    Abou-Issa H; Curley RW; Panigot MJ; Wilcox KA; Webb TE
    Anticancer Res; 1993; 13(5A):1431-6. PubMed ID: 8239515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved synthesis of the C-linked glucuronide of N-(4-hydroxyphenyl)retinamide.
    Walker JR; Alshafie G; Abou-Issa H; Curley RW
    Bioorg Med Chem Lett; 2002 Sep; 12(17):2447-50. PubMed ID: 12161154
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potent anticancer activities of novel aminophenol analogues against various cancer cell lines.
    Ohba T; Yamauch T; Higashiyama K; Takahashi N
    Bioorg Med Chem; 2007 Jan; 15(2):847-53. PubMed ID: 17092729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of short retinoidal amides related to fenretinide: antioxidant activities and differentiation-inducing ability.
    Anzaldi M; Viale M; Macciò C; Castagnola P; Oliveri V; Rosano C; Balbi A
    Cancer Chemother Pharmacol; 2017 Apr; 79(4):725-736. PubMed ID: 28275870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.